$TLSA News

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

Tiziana Life Sciences Completes Enrollment In Phase 2a Trial Of Intranasal Foralumab For Secondary Progressive Multiple Sclerosis, With Topline Data Expected In Q3 2026

Tiziana Life Sciences price target boosted on foralumab update

Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS

Tiziana Announces New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis

Tiziana Life Sciences' Updated Data From Its Ongoing Expanded Access Program Of Intranasal Foralumab For Non-Active Secondary Progressive Multiple Sclerosis Shows Encouraging Trends In Stabilization Of Disability And Meaningful Improvements In Fatigue

Tiziana Reports Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab

Tiziana Life Sciences Announces Initial Quantitative PET Imaging Results From The First Two Patients With Multiple System Atrophy In Its Phase 2 Clinical Trial Of Forlumab

Inventiva Builds Up Leadership Team Ahead of Potential Commercialization

Tiziana says intranasal drug shows potential to ease Long COVID “brain fog”

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

Tiziana Life Sciences Announces Publication Of Preclinical Data Showing Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation And Improves Cognitive Function

Tiziana Life Sciences shares are trading higher after the company announced a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy has been accepted for presentation at the 7th World Parkinson Congress.

Tiziana Life Sciences shares are trading higher after the company announced a late-breaking poster on its Phase 2a study of intranasal foralumab in Multiple System Atrophy has been accepted for presentation at the 7th World Parkinson Congress.

Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress

Tiziana Life Sciences to present Phase 2a MSA study at World Parkinson Congress

Tiziana Life Sciences To Present Data From Phase 2a Study Of Intranasal Foralumab In Multiple System Atrophy at World Parkinson Congress In May 2026